Dr. Yubin Zhou's Caffeine-Guided Gene Research Featured on Heliox Podcast

Dr. Yubin Zhou, professor and director of the Center for Translational Cancer Research at the Institute of Biosciences and Technology (IBT) at Texas A&M University, was featured on the Heliox: Where Evidence Meets Empathy podcast discussing IBT-developed technology that uses caffeine to control engineered cells and gene-editing systems.

From Laboratory Discovery to Public Conversation

In the episode "Your Morning Cup Just Became a Medical Device: Caffeine vs. Cancer", hosts Scott Bleackley and Michelle Bruecker explored how Texas A&M Health researchers are developing caffeine-activated tools that could make future cell therapies safer and more controllable.

The conversation builds on peer-reviewed work from the Zhou laboratory and related coverage in Vital Record, the official news publication of Texas A&M University Health. The research describes an artificial intelligence-assisted approach to designing caffeine-responsive genetic switches, offering a practical way to turn engineered cell activity on or off using a widely available dietary compound.

Why Caffeine-Guided Control Matters

Engineered cell therapies and CRISPR-based tools hold promise for treating cancer and other diseases, but clinicians need precise control over when those tools are active. Caffeine-activated safety switches could allow researchers and, eventually, care teams to regulate therapeutic cells with a familiar, low-cost trigger.

For IBT, the podcast is one of many outlets reporting on the Zhou laboratory's translational cancer research. Additional coverage is summarized on the Zhou Laboratory news page, including reports from GEN, ScienceDaily, and other science media.

Learn More

Faculty profile: Dr. Yubin Zhou at IBT